Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Objective To evaluate whether a disease activity guided strategy of dose reduction of two tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in maintaining disease control in patients with rheumatoid arthritis compared with usual care. Design Randomised controlled, op...

Descripción completa

Detalles Bibliográficos
Autores principales: van Herwaarden, Noortje, van der Maas, Aatke, Minten, Michiel J M, van den Hoogen, Frank H J, Kievit, Wietske, van Vollenhoven, Ronald F, Bijlsma, Johannes W J, van den Bemt, Bart J F, den Broeder, Alfons A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391970/
https://www.ncbi.nlm.nih.gov/pubmed/25858265
http://dx.doi.org/10.1136/bmj.h1389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391970/
https://www.ncbi.nlm.nih.gov/pubmed/25858265
http://dx.doi.org/10.1136/bmj.h1389

Ejemplares similares